Showing results (341-350 of 515) with videos related to
Sort By:
Pageof 52
Journal of Hypertension|October 3, 2002
The Framingham prediction rule is not valid in a European population of treated hypertensive patientsSylvie Bastuji-Garin, Anne Deverly, Dominique Moyse, et al.Hypertension (Dallas, Tex. : 1979)|July 22, 2009
Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertensionKerstin Wustmann, Jan P Kucera, Ingrid Scheffers, et al.Microvascular Research|April 26, 2011
Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individualsAmy M Jonk, Alfons J Houben, Nicolaas C Schaper, et al.Journal of the American College of Cardiology|August 6, 2011
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trialJohn D Bisognano, George Bakris, Mitra K Nadim, et al.Microvascular Research|August 31, 2011
Obesity is associated with impaired endothelial function in the postprandial stateAmy M Jonk, Alfons J Houben, Nicolaas C Schaper, et al.Hypertension (Dallas, Tex. : 1979)|June 18, 2003
Is there a side predilection for cerebrovascular disease?Sergio A Rodríguez Hernández, Abraham A Kroon, Martin P J van Boxtel, et al.Journal of Hypertension|November 1, 1993
Vascular distensibility and compliance in salt-sensitive and salt-resistant borderline hypertensionP Draaijer, M J Kool, J M Maessen, et al.Journal of Hypertension|November 4, 2006
Prevalence of the white-coat effect at multiple visits before and during treatmentWillem J Verberk, Abraham A Kroon, Theo Thien, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 9, 2016
Arterial stiffness and decline of renal function in a primary care populationBernard J van Varik, Liv M Vossen, Roger J Rennenberg, et al.Journal of Cardiovascular Pharmacology|November 1, 1994
Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failureW J Remme, D A Kruijssen, D C van Hoogenhuyze, et al.Pageof 52